News and Trends 31 Aug 2022 Gel treatment for erectile dysfunction receives positive results from clinical trial Futura Medical has announced positive results from a clinical trial looking into MED3000, a topical gel formulation for the treatment of erectile dysfunction (ED). The results, from the confirmatory phase 3 clinical study, FM71, were announced today (August 31). MED3000 is a breakthrough, fast-acting gel produced by Futura Medical’s transdermal DermaSys drug delivery technology. It […] August 31, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 30 Aug 2022 Artificial intelligence-based algorithm to be used for reporting of lymph node status in colon cancer A collaboration looking at the development of an artificial intelligence (AI)-based digital pathology solution to detect cancer within lymph nodes from colorectal surgery cases has been announced today (August 30). Indica Labs, which works in quantitative digital pathology and image management solutions, has joined forces with The Industrial Centre for Artificial Intelligence Research in Digital […] August 30, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 30 Aug 2022 Hemophilia drug from Sanofi and Sobi has license application accepted for priority review by FDA The Biologics License Application (BLA) for Efanesoctocog alfa, a drug to treat the rare and life-threatening blood disease, hemophilia A, has been accepted for priority review by the U.S. Food and Drug Administration (FDA). Efanesoctocog alfa (BIVV001) is being developed and commercialized as part of a collaboration between Sanofi and Sobi was given the target […] August 30, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 29 Aug 2022 Vilya emerges to target disease biology VILYA, Inc. (Vilya), a biotech company aiming to create a new class of medicines to precisely target disease biology, launched today. Vilya is co-founded by scientists from the Institute of Protein Design (IPD) led by David Baker, and ARCH Venture Partners. The company’s platform, powered by advanced machine learning, taps into uncharted chemical space to […] August 29, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Aug 2022 Grid Biosciences signs agreement with NIH for Epstein-Barr virus vaccine Grid Biosciences has signed a license agreement for the development of a vaccine against Epstein-Barr virus (EBV) with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The agreement includes access to NIH’s patent rights in EBV envelope proteins that the virus uses to gain entry into […] August 29, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Aug 2022 AIVITA Biomedical announces publication of trial results of its COVID-19 vaccine Safety and efficacy results from phase 1 and 2 clinical trials looking at a Covid-19 vaccine made at point-of-care by third party personnel have been published. AIVITA Biomedical Inc., a biotech specializing in cell applications, made the announcement today (August 29). The results were published in the article in the journal Human Vaccines & Immunotherapeutics. […] August 29, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 26 Aug 2022Beyond Biotech podcast 11: Ilya Pharma, IRB Barcelona, Krystal Biotech, Phase Genomics This week it’s another four interview podcast, and the introduction of a new feature. Our guests are Ilya Pharma CEO and co-founder Evelina Vågesjö and chief financial officer Oskar Lund; Miguel Martín-Álvarez, postdoctoral fellow in the cancer science unit at IRB Barcelona; Hubert Chen, head of clinical development at Krystal Biotech; and Ivan Liachko, CEO […] August 26, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 26 Aug 2022 Cholesterol targeting antibodies produced by Bio-Rad Laboratories Antibodies that target a protein playing a key role in the regulation of cholesterol levels have been introduced by Bio-Rad Laboratories. The range of type 1 antibodies inhibit the binding of evolocumab (Repatha) to its target – human proprotein convertase subtilisin/kevin type 9 (PCSK9). Recombinant antibodies These sequence-defined, recombinant antibodies are suitable for developing highly […] August 26, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 26 Aug 2022 Ordaōs raises $5M to accelerate drug design and discovery U.S. biotech company Ordaōs has raised $5 million in seed financing to aid in new product development and expand partner acquisition efforts. The oversubscribed round was led by Middleland Capital’s VTC Ventures with additional investments from Route 66 Ventures, Banyan Pacific Capital, IAG Capital Partners, and Citta Capital. Ordaōs is a drug design company that […] August 26, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 Aug 2022 Hope for children with chronic graft versus host disease as Johnson & Johnson drug approved A treatment for chronic graft versus host disease in children aged one year and older has been approved by the U.S. Food and Drug Administration (FDA). Graft versus host disease is a common complication after receiving a donor stem-cell or bone marrow transplantation. Sometimes, the graft doesn’t recognize the host as being friendly and sees the […] August 25, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 25 Aug 2022 3T Biosciences launches with $40M financing 3T Biosciences wants to change the future of treatment for solid tumors and other immune-mediated diseases. And it exited from stealth today backed by $40 million in series A financing led by Westlake Village BioPartners with participation from Lightspeed Venture Partners. Proceeds from the financing will be used to help accelerate 3T Biosciences from a […] August 25, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Aug 2022 Hera Biotech bags $1.9M for endometriosis diagnostic test San Antonio-based medical device start-up Hera Biotech has closed an oversubscribed $1.9 million seed financing round to support its commercialization strategy for its non-surgical diagnostic test for endometriosis, MetriDx. The funds will be used to complete an in-patient human clinical study, expand Hera’s IP portfolio, and support a regulatory pathway with the U.S. FDA. Investors […] August 24, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email